The CCND1 G870A Gene Polymorphism and Brain Tumor Risk: a Meta-analysis

  • Qin, Ling-Yan ;
  • Zhao, Li-Gang ;
  • Chen, Xu ;
  • Li, Ping ;
  • Yang, Zheng ;
  • Mo, Wu-Ning
  • Published : 2014.04.30


Background: In recent years, numerous studies have been performed to investigate the CCND1 G870A gene polymorphism impact on brain tumors susceptibility. Unfortunately, the results of previous studies were inconsistent. Therefore, we performed a meta-analysis to derive a more precise estimation of any association. Materials and Methods: We conducted a search in PubMed, Embase and CNKI covering all published papers up to November, 2013. Odds ratios (ORs) and their 95% confidence intervals (95%CIs) were applied to assess associations. Results: A total of 6 publications including 9 case-control studies met the inclusion criteria. The pooled ORs for the total included studies showed significant association among comparison A vs G (OR= 1.246, 95%CI= 1.092-1.423, p= 0.001), homozygote comparison AA vs GG (OR= 1.566, 95%CI= 1.194-2.054, p= 0.001), heterozygote comparison AG vs GG (OR= 1.290, 95%CI= 0.934-1.782, p= 0.122), dominant model AA/GA vs GG (OR= 1.381, 95%CI= 1.048-1.821, p= 0.022) and recessive model AA vs GA/GG (OR= 1.323, 95%CI= 1.057-1.657, p= 0.015) especially in glioma. Conclusions: CCND1 G870A polymorphism may increase brain tumor risk, especially for gliomas. However, more primary large scale and well-designed studies are still required to evaluate the interaction of CCND1 G870A polymorphism with brain tumor risk.


Brain tumors;cyclin D1 gene;polymorphism;meta-analysis


  1. Zeybek U, Yaylim I, Ozkan NE, et al (2013). Cyclin D1 gene G870A variants and primary brain tumors. Asian Pac J Cancer Prev, 14, 4101-6.
  2. Wang L, Habuchi T, Mitsumori K, et al (2003). Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer, 103, 116-20.
  3. Wang Y, Li Z, Liu N, et al (2014). Association between CCND1 and XPC polymorphisms and bladder cancer risk: a metaanalysis based on 15 case-control studies. Tumour Biol, 35, 3155-65.
  4. Yang Y, Wang F, Shi C, et al (2012). Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case-control studies. Plos One, 7, 36813.
  5. Sadetzki S, Flint-Richter P, Starinsky S, et al (2005). Genotyping of patients with sporadic and radiationassociated meningiomas. Cancer Epidemiol Biomarkers Prev, 14, 969-76.
  6. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  7. Qiuling S, Yuxin Z, Suhua Z, et al (2003). Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis, 24, 1499-503.
  8. Rajaraman P, Wang SS, Rothman N, et al (2007). Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev, 16, 1655-61.
  9. Sherr CJ (1995). D-type cyclins. Trends Biochem Sci, 20, 187-90.
  10. Simpson DJ, Fryer AA, Grossman AB, et al (2001). Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis, 22, 1801-7.
  11. Solomon DA, Wang Y, Fox SR, et al (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 278, 30339-47.
  12. Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 469.
  13. Tobias A, Campbell MJ (1999). Modelling influenza epidemics in the relation between black smoke and total mortality. A sensitivity analysis. J Epidemiol Community Health, 53, 583-4.
  14. Vogelstein B, Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med, 10, 789-99.
  15. Donnellan R, Chetty R (1998). Cyclin D1 and human neoplasia. Mol Pathol, 51, 1-7.
  16. Daly AF, Rixhon M, Adam C, et al (2006). High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab, 91, 4769-75.
  17. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  18. Diehl JA (2002). Cycling to cancer with cyclin D1. Cancer Biol Ther, 1, 226-31.
  19. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  20. Evan GI, Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8.
  21. Galbraith RF (1988). A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med, 7, 889-94.
  22. Gazioglu NM, Erensoy N, Kadioglu P, et al (2007). Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Med Sci Monit, 13, 457-63.
  23. Gijtenbeek JM, Boots-Sprenger SH, Franke B, et al (2005). Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol, 74, 261-6.
  24. Inskip PD, Linet MS, Heineman EF (1995). Etiology of brain tumors in adults. Epidemiol Rev, 17, 382-414.
  25. Kong S, Amos CI, Luthra R, et al (2000). Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res, 60, 249-52.
  26. Liu J, Liao Q, Zhang Y, et al (2012). Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis. Tumour Biol, 33, 1467-76.
  27. Betticher DC, Thatcher N, Altermatt HJ, et al (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene, 11, 1005-11.
  28. Akkiz H, Bayram S, Bekar A, et al (2010). Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: casecontrol study. Cancer Epidemiol, 34, 298-302.
  29. Bala S, Peltomaki P (2001). CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res, 61, 6042-5.
  30. Bedewy AM, Mostafa MH, Saad AA, et al (2013). Association of cyclin D1 A870G polymorphism with two malignancies:acute lymphoblastic leukemia and breast cancer. J BUON, 18, 227-38.
  31. Bondy ML, Scheurer ME, Malmer B, et al (2008). Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer, 113, 1953-68.
  32. Cander S, Erturk E, Karkucak M, et al (2012). Effect of cycline D1 (CCND1) gene polymorphism on tumor formation and behavior in patients with prolactinoma. Gene, 509, 158-63.
  33. Catarino R, Coelho A, Nogueira A, et al (2012). Cyclin D1 polymorphism in non-small cell lung cancer in a Portuguese population. Cancer Biomark, 12, 65-72.
  34. Chen B, Cao L, Yang P, et al (2012). Cyclin D1 (CCND1) G870A gene polymorphism is an ethnicity-dependent risk factor for digestive tract cancers: a meta-analysis comprising 20, 271 subjects. Cancer Epidemiol, 36, 106-15.
  35. Chen X, Zhao T, Li L, et al (2012). CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. DNA Cell Biol, 31, 1107-13.

Cited by

  1. Association of Cyclin D1 Variants with Head and Neck Cancer Susceptibility: Evidence from a Meta-analysis vol.15, pp.14, 2014,
  2. Association Between PARP1 Single Nucleotide Polymorphism and Brain Tumors vol.53, pp.4, 2016,